Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.

"Conflict-of-interest disclosure: C.D.D. has been a board of directors or advisory committee member for Genmab, GlaxoSmithKline, Kura Oncology, and Notable Labs; has received honoraria from Kura, Astellas Pharma, bluebird bio, Bristol Myers Squibb, Foghorn Therapeutics, Immune-Onc Therapeutics, Novartis, Takeda Oncology, Gilead Sciences, and Jazz Pharmaceuticals; is a current holder of stock options for Notable Labs; has been a consultant for AbbVie and Servier; and has received research funding from Servier, 10.13039/100002491Bristol Myers Squibb, 10.13039/100016346Foghorn, Immune-Onc Therapeutics, 10.13039/100016936Loxo Oncology, 10.13039/100013870Astex Pharmaceuticals, Cleave, and Forma. A.M. reports support from BioSight, 10.13039/100004339Sanofi, and 10.13039/100013870Astex Pharmaceuticals. G.B. has received research funding from 10.13039/100013870Astex Pharmaceuticals, Ryvu Therapeutics, and 10.13039/100013223PTC Therapeutics; has been a board of directors or advisory committee member for Pacyclex Pharmaceuticals, Novartis, CytomX, and Bio Ascend; and has been a consultant for Catamaran Bio, AbbVie, PPD Development, Protagonist Therapeutics, and Janssen. N.S. has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer; received research funding from 10.13039/100011957Takeda Oncology, Astellas, and Stemline Therapeutics; and received honoraria from Amgen. K.T. has been a consultant for SymBio Pharmaceuticals; and received honoraria from Mission Bio, Illumina, and Otsuka Pharmaceutical. N.G.D. has received research funding from 10.13039/501100004948Astellas Pharma, 10.13039/100006483AbbVie, 10.13039/100004328Genentech, 10.13039/501100022274Daiichi Sankyo, 10.13039/100005564Gilead Sciences, 10.13039/100019203ImmunoGen, 10.13039/100004319Pfizer, 10.13039/100002491BristolMyers Squibb, Trovagene, 10.13039/501100011725Servier, Novimmune, 10.13039/100017655Incyte, Hanmi Pharm, Fate Therapeutics, 10.13039/100002429Amgen, 10.13039/100014481Kite Pharma, 10.13039/100004336Novartis, 10.13039/100013870Astex Pharmaceuticals, KAHR, Shattuck, 10.13039/501100012112Sobi, GlycoMimetics, and Trillium; has been an adviser for Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Jazz Pharmaceuticals, Amgen, Servier, Karyopharm Therapeutics, Trovagene, Trillium, Syndax, Gilead Sciences, Pfizer, Bristol Myers Squibb, Kite Pharma, Actinium Pharmaceuticals, Arog Pharmaceuticals, ImmunoGen, Arcellx, and Shattuck; has been a data-monitoring committee member for Kartos Therapeutics and Jazz Pharmaceuticals; has been a consultant or board of directors or advisory committee member for Agios, Celgene, Sobi, and STAR Therapeutics; and has received research funding from Karyopham Therapeutics and Newave Pharmaceutical. G.I. has been a consultant for Novartis, Kura Oncology, and NuProbe and received research funding from 10.13039/100006436Celgene, Kura Oncology, 10.13039/100018201Syndax, 10.13039/100004334Merck, Cullinan Oncology, and 10.13039/100004336Novartis. N.P. has been a consultant for AbbVie, Astellas Pharma, Cimeio Therapeutics, CTI BioPharma, ImmunoGen, Intellisphere, Patient Power, PharmaEssentia, Protagonist Therapeutics, and TotalCME; has been a scientific/advisory committee member for Blueprint Medicines, Cancer.Net, CareDx, CTI BioPharma, Incyte, Menarini Group, and Pacylex Pharmaceuticals; has been a speaker or held a preceptorship for AbbVie, the Aplastic Anemia & MDS International Foundation, Curio Bioscience, DAVA Oncology, Intellisphere, Magdalen Medical Publishing, Medscape, Novartis, the Physician's Education Resource, Protagonist Therapeutics, and Targeted Oncology; and has received research support from the 10.13039/100000005US Department of Defense. M.Y. has received research funding from 10.13039/501100002973Daiichi-Sankyo and 10.13039/100004319Pfizer. G.G.-M. has received research funding from 10.13039/100013870Astex Pharmaceuticals, 10.13039/100004336Novartis, 10.13039/100006483AbbVie, 10.13039/100002491Bristol Myers Squibb, 10.13039/100004328Genentech, Aprea Therapeutics, Curis, and 10.13039/100005564Gilead Sciences; has been a consultant for Astex Pharmaceuticals, Acceleron Pharma, and Bristol Myers Squibb; and has received honoraria from Astex Pharmaceuticals, Acceleron Pharma, AbbVie, Novartis, Gilead Sciences, Curis, Genentech, and Bristol Myers Squibb. F.R. has received research funding from 10.13039/100002429Amgen, 10.13039/100013870Astex Pharmaceuticals/Taiho Oncology, 10.13039/100002491Bristol Myers Squibb/10.13039/100006436Celgene, Syos, 10.13039/100006483AbbVie, Prelude, Xencor, 10.13039/501100004948Astellas Pharma, and Biomea Fusion; honoraria from Amgen, Bristol Myers Squibb/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals/Taiho Oncology; and has been a consultant for Bristol Myers Squibb/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma. H.M.K. has received research funding from 10.13039/100006483AbbVie, 10.13039/100002429Amgen, 10.13039/100019621Ascentage Pharma, 10.13039/100002491Bristol Myers Squibb, 10.13039/501100022274Daiichi Sankyo, 10.13039/100019203ImmunoGen, 10.13039/100011096Jazz Pharmaceuticals, and 10.13039/100004336Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision BioSciences, Shenzhen TargetRx, and Takeda Oncology. T.M.K. has been a consultant for AbbVie, Agios, Bristol Myers Squibb, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from 10.13039/100006483AbbVie, 10.13039/100002491Bristol Myers Squibb, 10.13039/100004328Genentech, 10.13039/100011096Jazz Pharmaceuticals, 10.13039/100004319Pfizer, Cellenkos, 10.13039/100019621Ascentage Pharma, 10.13039/100022781Galectin Therapeutics, 10.13039/501100004948Astellas Pharma, 10.13039/100004325AstraZeneca, 10.13039/100002429Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, 10.13039/100019194Iterion Therapeutics, GlycoMimetics, and 10.13039/100009857Regeneron Pharmaceuticals; and has received honoraria from Astex Pharmaceuticals. The remaining authors declare no competing financial interests."

"This study was partly funded by the Rama Guntupalli Endowment for Leukemia Research."